Having established that UPS and glutamine-sensitive STS subtypes express higher GLS levels, we determined whether a small molecule GLS inhibitor, Telaglenastat (CB-839), currently in clinical trials for multiple cancer types, is effective in causing UPS and STS cell death. Here, GLS is linked to cancer.